



PLEASE DISTRIBUTE TO YOUR HEALTHCARE PROVIDERS

URGENT HEALTH BULLETIN

Monkeypox (MPX) Vaccination and Treatment Update

This document contains hyperlinks and can be accessed on our [Health Bulletin webpage \(https://kernpublichealth.com/health-bulletin/\)](https://kernpublichealth.com/health-bulletin/) and [Monkeypox Webpage for Healthcare Providers \(https://kernpublichealth.com/monkeypox/providers/\)](https://kernpublichealth.com/monkeypox/providers/)

September 20, 2022

Dear Kern County Healthcare Provider:

- **Monkeypox (MPX) Vaccination Eligibility**

While JYNNEOS vaccine supply continues to be limited, all healthcare workers, laboratory workers, and public health responders who may be exposed to MPX are eligible for vaccination against MPX in Kern County. Additional eligibility groups are outlined on the Kern County Public Health Services Department (KCPHSD) [MPX webpage](#). Vaccination events are scheduled at the Richard Prado Senior Center/East Bakersfield Veteran's Hall from 10:00 am to 4:00 pm on Wednesday, September 21, 2022 and Wednesday, September 28, 2022. The link to both clinics can be accessed directly [here](#) or on the [MPX webpage](#). Additional clinics dates can also be found on <https://myturn.ca.gov/>.

- **MPX Vaccine Redistribution**

Healthcare providers who are interested in administering JYNNEOS vaccine to patients can email monkeypox@ph.kerncounty.com or call 661-321-3000 to request vaccine. Providers must review and agree to the CDC [Monkeypox Vaccination Agreement](#) and [updates](#) posted online. Providers must also review the [JYNNEOS prescribing information](#) and FDA [Emergency Use Authorization](#) for intradermal administration and use in children under the age of 18. In accordance with the [provider letter](#) issued to update the current package insert, JYNNEOS may be stored frozen (-13°F to 5°F) until expiration and can also be stored for up to 8 weeks refrigerated (36°F - 46°F) instead of 12 hours refrigerated that may be noted on original packaging. Providers must abide by the county eligibility criteria found on the main [MPX webpage](#) and routinely check for eligibility updates.

For urgent redistribution of JYNNEOS for post-exposure prophylaxis of an exposed patient after hours, on holidays, or on weekends, call 661-241-3255 to reach Public Health On-Call staff.

- **MPX Treatment Options**

TPOXX (tecovirimat) continues to be available in both oral and IV formulations for the treatment of high-risk patients under the expanded access investigational new drug (EA-IND) protocol. To request TPOXX, healthcare providers can email monkeypox@ph.kerncounty.com or call 661-321-3000. Providers must review the CDC [Interim Clinical Guidance for Treatment of Monkeypox](#), the CDC [Guidance for](#)

[Tecovirimat Use Under Expanded Access Investigational New Drug Protocol](#), the CDC [Information for Healthcare Providers on Obtaining and Using TPOXX \(Tecovirimat\) for Treatment of Monkeypox](#). Providers must also review the [TPOXX prescribing information](#) and the FDA [Monkeypox Response Therapeutics Section](#), including the risk of Viral Resistance section. Patients must complete the [informed consent form](#) prior to administration of TPOXX; however, treatment can be started while the rest of the EA-IND paperwork is being completed. Tecovirimat treatment may be started in patients with high clinical suspicion of MPX infection and or those with significant epidemiological risk factors while testing is pending.

For urgent redistribution of TPOXX for a high-risk patient after hours, on holidays, or on weekends, call 661-241-3255 to reach Public Health On-Call staff.

Other treatment options including Vaccinia Immune Globulin (VIG), cidofovir (Vistide) and brincidofovir (CMX001 or Tembexa) may be considered. While these treatments are licensed and approved by FDA for treatment of specific conditions, including illnesses caused by orthopoxvirus, there is no data on the effectiveness of any these treatments specifically on MPX infection.

- **TPOXX as Post-Exposure Prophylaxis (PEP)**

TPOXX may be considered for use as PEP in rare circumstances, such as when vaccine is contraindicated due to an allergy to vaccine components. Per the [EA-IND Protocol](#), healthcare providers must consult with CDC prior to using TPOXX used as PEP. Contact the CDC Emergency Operations Center at 770-488-7100 or poxvirus@cdc.gov to arrange consultation.

- **MPX Resources**


This continues to be an evolving situation. Please refer to the [Kern County MPX Page for Healthcare Providers](#), [CDC](#), and [CDPH](#) webpages for the most up-to-date information.

[CDPH September 9, 2022 CAHAN](#)
[CDPH August 30, 2022 CAHAN](#)
[CDC July 30, 2022 HAN](#)
[KCPHSD July 29, 2022 Urgent Health Bulletin](#)
[CDC July 28, 2022 HAN](#)

[KCPHSD July 9, 2022 Urgent Health Bulletin](#)
[CDPH June 23, 2022 CAHAN](#)
[KCPHSD June 16, 2022 Urgent Health Bulletin](#)
[CDC June 14, 2022 HAN](#)
[CDC May 20, 2022 HAN](#)

If you have any questions, please contact KCPHSD by phone at 661-321-3000, via email at publichealth@kerncounty.com, or visit our [KCPHSD website](#).

Thank you,


Kristopher Lyon, MD
Health Officer